Coronary Artery DiseaseNCT07063628
Triglyceride-Glucose Indices and Left Ventricular Speckle Tracking in Predicting Coronary Artery Disease Severity
An observational study of Coronary Artery Disease, run by Damanhour University at 1 site in Egypt.
Trial summary
Our study specifically will address the value of modified triglyceride glucose indices versus left ventricular speckle tracking in prediction of severity of coronary artery disease assessed by Gensini score. Read more about this study
- Who is it for?
- Ages 38 to 80 years
- Conditions the study is for
- Coronary Artery Disease
- What is being tested?
- TyG-derived index. and Left Ventricular Speckle Tracking
- How many people
- 508 participants
- Where
- 1 siteEgypt
- Study dates
- 30 Apr 2025to 3 Jul 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 38 to 80 years
- All sexes
- Adult, Older adult
Study population: Two hundred adult patients with chronic stable angina and angiographically confirmed coronary artery disease (CAD) were enrolled.
Who may be able to join
- diagnosis of CAD with ≥50% stenosis in at least one major coronary artery.
Who cannot join
- Patients with acute coronary syndrome, arrhythmias, previous coronary interventions (PCI or CABG), or inability to undergo echocardiographic assessment.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Comparative Assessment of Triglyceride-Glucose Indices and Left Ventricular Speckle Tracking in Predicting Coronary Artery Disease Severity: Insights From Gensini Scoring
Our study specifically will address the value of modified triglyceride glucose indices versus left ventricular speckle tracking in prediction of severity of coronary artery disease assessed by Gensini score.
Read the detailed description
A cross sectional study that will be conducted in Cardiovascular Department of Tanta University in Egypt in the period from May to July 2025 . Two hundred patients diagnosed with coronary artery diseases were included in the study. Patients were considered to have confirmed coronary artery disease through angiographically proven CAD.
Provision of privacy:
Privacy of all data is guaranteed and there will be a code number for every patient and include all of his or her investigations.
Informed consent:
Informed written consent will be obtained from all patients after full explanation of benefits and risks of the study.
Methods: Study patients and procedures:
Selection criteria included any patient with chronic stable angina and proved coronary artery disease by coronary angiography Exclusion criteria included: Any patients with acute coronary syndrome, arrhythmias, previous Percutaneous coronary intervention (PCI) or Coronary Artery Bypass Graft (CABG) surgery
All the participants were subjected to following:
- History taking for presence of risk factors of cardio vascular disease as age, sex, smoking, physical inactivity, diabetes and hypertension.
- Physical examination including height, weight and waste circumference
- Resing 12 leads ECG
- Laboratory investigations:
- Fasting blood glucose (FBG)
- Triglyceride (TG), TG index.
- Total Cholesterol level
- Renal Function test . Echocardiographic evaluation
- Coronary angiography 7. Gensini score calculated by summation of the individual coronary segment scores.
- Conditions
- Coronary Artery Disease
- Being tested
- TyG-derived index., Left Ventricular Speckle Tracking
- Medical subject headings
- Coronary Artery Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
TyG-derived index.Diagnostic test
Also called TG index
Derived indices included:
- Ty,G×B,M,I = TyG index × body mass index
- TyG×W,C = TyG index × waist circumference
- TyG×WH,tR = TyG index × waist-to-height ratio Quartile-based stratification was applied to each TyG-derived index.
Left Ventricular Speckle TrackingDiagnostic test
Also called Echocardiographic Assessment
Coronary Angiography and Gensini Scoring: All participants underwent standard diagnostic coronary angiography. CAD was categorized as one-, two-, or three-vessel disease based on the number of vessels with ≥50% stenosis. The severity of CAD was quantified using the Gensini score, which assigns a severity weight to each lesion depending on degree of stenosis and anatomical location. Final scores were calculated by summing weighted values across all coronary segments.
What is being measured
The primary outcome is the main question the study is designed to answer.
triglyceride-glucose (TyG) index
predictive value of the triglyceride-glucose (TyG) index and its modified forms (TyG×BMI, TyG×WC, TyG, ×, W,Ht,R ) with global longitudinal strain (GLS) in assessing coronary artery disease (CAD) severity, as quantified by the Gensini score.
Measured: 2 months
longitudinal strain (GLS)
Echocardiography parameter in assessing coronary artery disease (CAD) severity
Measured: 2 months
Gensini score.
Score assessing coronary artery disease (CAD) severity
Measured: 2 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start30 Apr 2025
- Primary completion1 Jul 2025
- Study completion3 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Coronary Artery DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 508 participants (actual)
Sponsor and investigators
- Lead sponsor
- Damanhour University
- Sponsor type
- University, hospital or other
- Collaborators
- Tanta University
- Responsible party
- Principal investigator, Rehab Werida, Damanhour University
- Investigators
- Eman Elshaikh, Ass. Prof., Principal investigator, Tanta University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07063628
- Sponsor's protocol ID
- Predicting CAD Severity
- Status last verified
- Jul 2025
- First submitted
- 3 Jul 2025
- Last updated
- 16 Jul 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Siverio-Morales O, Mora-Fernandez C, Hernandez-Carballo C, Martin-Nunez E, Gonzalez-Luis A, Martin-Olivera A, Navarro-Gonzalez JF, Donate-Correa J. Predictive value of triglyceride-glucose index for the evaluation of coronary artery disease severity and occurrence of major adverse cardiovascular events. Am J Physiol Heart Circ Physiol. 2025 Jan 1;328(1):H14-H20. doi: 10.1152/ajpheart.00684.2024. Epub 2024 Nov 19.
PubMed 39560964Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum A, Barbarash O, Chifamba J, Diaz ML, Gulec S, Ismail N, Iqbal R, Kelishadi R, Khatib R, Lanas F, Levitt NS, Li Y, Mohan V, Mony PK, Poirier P, Rosengren A, Soman B, Wang C, Wang Y, Yeates K, Yusuf R, Yusufali A, Zatonska K, Rangarajan S, Yusuf S. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023 Jan;4(1):e23-e33. doi: 10.1016/S2666-7568(22)00247-1. Epub 2022 Dec 12.
PubMed 36521498Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, Teliewubai J, Zhang Y, Xu Y. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study. Cardiovasc Diabetol. 2019 Jul 25;18(1):95. doi: 10.1186/s12933-019-0898-x.
PubMed 31345238
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Assessment of Triglyceride-Glucose Indices and Left Ventricular Speckle Tracking in Predicting Coronary Artery Disease Severity: Insights From Gensini Scoring
- ClinicalTrials.gov ID
- NCT07063628
- Acronym / sponsor ID
- Predicting CAD Severity
- Conditions
- Coronary Artery Disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 508 participants (actual)
- Lead sponsor
- Damanhour UniversityUniversity, hospital or other
- Collaborators
- Tanta University
- Study start
- 30 Apr 2025 (actual)
- Primary completion
- 1 Jul 2025 (actual)
- Study completion
- 3 Jul 2025 (actual)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Our study specifically will address the value of modified triglyceride glucose indices versus left ventricular speckle tracking in prediction of severity of coronary artery disease assessed by Gensini score.
Detailed description
A cross sectional study that will be conducted in Cardiovascular Department of Tanta University in Egypt in the period from May to July 2025 . Two hundred patients diagnosed with coronary artery diseases were included in the study. Patients were considered to have confirmed coronary artery disease through angiographically proven CAD.
Provision of privacy:
Privacy of all data is guaranteed and there will be a code number for every patient and include all of his or her investigations.
Informed consent:
Informed written consent will be obtained from all patients after full explanation of benefits and risks of the study.
Methods: Study patients and procedures:
Selection criteria included any patient with chronic stable angina and proved coronary artery disease by coronary angiography Exclusion criteria included: Any patients with acute coronary syndrome, arrhythmias, previous Percutaneous coronary intervention (PCI) or Coronary Artery Bypass Graft (CABG) surgery
All the participants were subjected to following:
- History taking for presence of risk factors of cardio vascular disease as age, sex, smoking, physical inactivity, diabetes and hypertension.
- Physical examination including height, weight and waste circumference
- Resing 12 leads ECG
- Laboratory investigations:
- Fasting blood glucose (FBG)
- Triglyceride (TG), TG index.
- Total Cholesterol level
- Renal Function test . Echocardiographic evaluation
- Coronary angiography 7. Gensini score calculated by summation of the individual coronary segment scores.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 38 to 80 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- Two hundred adult patients with chronic stable angina and angiographically confirmed coronary artery disease (CAD) were enrolled.
Key inclusion criteria (1 listed)
- diagnosis of CAD with ≥50% stenosis in at least one major coronary artery.
Key exclusion criteria (1 listed)
- Patients with acute coronary syndrome, arrhythmias, previous coronary interventions (PCI or CABG), or inability to undergo echocardiographic assessment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| TyG-derived index.Also: TG indexDerived indices included: * Ty,G×B,M,I = TyG index × body mass index * TyG×W,C = TyG index × waist circumference * TyG×WH,tR = TyG index × waist-to-height ratio Quartile-based stratification was applied to each TyG-derived index. | Diagnostic test | – |
| Left Ventricular Speckle TrackingAlso: Echocardiographic AssessmentCoronary Angiography and Gensini Scoring: All participants underwent standard diagnostic coronary angiography. CAD was categorized as one-, two-, or three-vessel disease based on the number of vessels with ≥50% stenosis. The severity of CAD was quantified using the Gensini score, which assigns a severity weight to each lesion depending on degree of stenosis and anatomical location. Final scores were calculated by summing weighted values across all coronary segments. | Diagnostic test | – |
Primary outcome
triglyceride-glucose (TyG) index
Time frame: 2 months
predictive value of the triglyceride-glucose (TyG) index and its modified forms (TyG×BMI, TyG×WC, TyG, ×, W,Ht,R ) with global longitudinal strain (GLS) in assessing coronary artery disease (CAD) severity, as quantified by the Gensini score.
longitudinal strain (GLS)
Time frame: 2 months
Echocardiography parameter in assessing coronary artery disease (CAD) severity
Gensini score.
Time frame: 2 months
Score assessing coronary artery disease (CAD) severity
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2025.
- Background: PubMed 39560964Siverio-Morales O, Mora-Fernandez C, Hernandez-Carballo C, Martin-Nunez E, Gonzalez-Luis A, Martin-Olivera A, Navarro-Gonzalez JF, Donate-Correa J. Predictive value of triglyceride-glucose index for the evaluation of coronary artery disease severity and occurrence of major adverse cardiovascular events. Am J Physiol Heart Circ Physiol. 2025 Jan 1;328(1):H14-H20. doi: 10.1152/ajpheart.00684.2024. Epub 2024 Nov 19.
- Background: PubMed 36521498Lopez-Jaramillo P, Gomez-Arbelaez D, Martinez-Bello D, Abat MEM, Alhabib KF, Avezum A, Barbarash O, Chifamba J, Diaz ML, Gulec S, Ismail N, Iqbal R, Kelishadi R, Khatib R, Lanas F, Levitt NS, Li Y, Mohan V, Mony PK, Poirier P, Rosengren A, Soman B, Wang C, Wang Y, Yeates K, Yusuf R, Yusufali A, Zatonska K, Rangarajan S, Yusuf S. Association of the triglyceride glucose index as a measure of insulin resistance with mortality and cardiovascular disease in populations from five continents (PURE study): a prospective cohort study. Lancet Healthy Longev. 2023 Jan;4(1):e23-e33. doi: 10.1016/S2666-7568(22)00247-1. Epub 2022 Dec 12.
- Background: PubMed 31345238Zhao S, Yu S, Chi C, Fan X, Tang J, Ji H, Teliewubai J, Zhang Y, Xu Y. Association between macro- and microvascular damage and the triglyceride glucose index in community-dwelling elderly individuals: the Northern Shanghai Study. Cardiovasc Diabetol. 2019 Jul 25;18(1):95. doi: 10.1186/s12933-019-0898-x.
- Individual participant dataSharing planned: No
Related trials for Coronary Artery Disease
Recruiting
Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)
Coronary Artery Disease, High Risk Percutaneous Coronary Intervention
Active, not recruitingObservational study
Post-Induction Low Cardiac Output Syndrome in Coronary Artery Bypass Graft Surgery
Cardiac Output, Low, Coronary Arterial Disease
RecruitingPhase 3
A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.
Coronary Artery Disease (CAD), Coronary Artery Bypass Graft Surgery(CABG)
Enrolling by invitationObservational study
Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study
Non-obstructive Coronary Disease, Acute or Chronic Coronary Artery Disease
Recruiting
Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma
Melanoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Eman Elshaikh, Ass. Prof. principal investigator
Tanta University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Coronary Artery Disease, run by Damanhour University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
triglyceride-glucose (TyG) index (time frame: 2 months). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07063628, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2025.